Medical device manufacturer NinePoint Medical Inc. has received FDA 510 (k) clearance for its volumetric optical coherence tomography (OCT) imaging system.
Medical device manufacturer NinePoint Medical Inc. has received FDA 510 (k) clearance for its volumetric optical coherence tomography (OCT) imaging system.
NinePoint’s Nvision VLE Imaging System is a tool for the evaluation of human tissue microstructure by providing 2-D, cross-sectional, real-time depth visualization, according to the company. It is the first volumetric OCT device cleared by the FDA for endoscopic imaging that uses a circumferential scanning technique and an automated pullback to generate cross-sectional and longitudinal images simultaneously in real-time, the company said.
The system can image under the mucosal surface at less than 10 micros resolution up to a tissue depth of 3mm, and can image circumferentially or helically up to 6cm in length in less than 100 seconds, the company said.
“The Nvision VLE Imaging System can provide high-resolution images of potentially diseased tissue, which are deeper than can be imaged with endoscopy alone,” Charles Carignan, MD, president and CEO of NinePoint Medical, said in a statement.
“Our initial focus is on providing physicians with higher-resolution cross sectional and longitudinal images of diseased tissue in the epithelium of various organs, which impacts millions of adults in the United States.”
Carignan said the company will be conducting clinical trials of the Nvision VLE Imaging System in 2012 with plans of a commercial launch in 2013.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.